Mario Sznol
#141,816
Most Influential Person Now
Researcher
Mario Sznol's AcademicInfluence.com Rankings
Mario Sznolphilosophy Degrees
Philosophy
#7430
World Rank
#10645
Historical Rank
Logic
#4479
World Rank
#5781
Historical Rank

Mario Sznolbiology Degrees
Biology
#10094
World Rank
#13386
Historical Rank
Immunology
#625
World Rank
#645
Historical Rank

Download Badge
Philosophy Biology
Why Is Mario Sznol Influential?
(Suggest an Edit or Addition)Mario Sznol's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. (2012) (10640)
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (2015) (3858)
- Nivolumab plus ipilimumab in advanced melanoma. (2013) (3808)
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. (2015) (2259)
- Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. (2014) (2043)
- High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. (1999) (1879)
- Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. (1995) (1249)
- Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma (2012) (1047)
- Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. (2015) (1015)
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. (2012) (963)
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. (2017) (806)
- Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. (2016) (781)
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) (750)
- Programmed death ligand-1 expression in non-small cell lung cancer (2014) (707)
- Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. (2002) (564)
- High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. (2000) (542)
- Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer (2013) (503)
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma (2016) (500)
- Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. (2016) (495)
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3 (2019) (445)
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. (2015) (400)
- Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. (2017) (367)
- Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo (2015) (355)
- Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. (2017) (347)
- Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab (2011) (323)
- Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors (2018) (320)
- Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab (2019) (316)
- Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas (2015) (309)
- Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. (2012) (300)
- Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205 (2014) (296)
- PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells (2010) (295)
- Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. (2010) (282)
- Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy (2015) (281)
- Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients (2017) (274)
- A clinical development paradigm for cancer vaccines and related biologics. (2007) (274)
- Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients (2003) (268)
- Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032 (2010) (264)
- Early B cell changes predict autoimmunity following combination immune checkpoint blockade (2018) (255)
- Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody (2016) (243)
- First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. (2017) (233)
- Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. (2017) (213)
- Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma (2016) (208)
- Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA) (2008) (203)
- Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. (1990) (203)
- Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. (2017) (201)
- Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. (1999) (194)
- Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites (2015) (184)
- Genome-wide screen of promoter methylation identifies novel markers in melanoma. (2009) (183)
- Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. (2014) (179)
- Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. (2017) (172)
- Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. (2019) (169)
- Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. (1993) (168)
- Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. (1996) (158)
- Use of preferentially replicating bacteria for the treatment of cancer. (2000) (154)
- A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. (1992) (147)
- Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors (2017) (145)
- Immunotherapy of Melanoma: Facts and Hopes (2019) (139)
- Blockade of the B7-H1/PD-1 Pathway for Cancer Immunotherapy (2011) (135)
- Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. (2017) (132)
- The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin (1993) (131)
- Bullous disorders associated with anti–PD‐1 and anti–PD‐L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy (2018) (129)
- Systemic Administration of an Attenuated, Tumor-Targeting Salmonella typhimurium to Dogs with Spontaneous Neoplasia: Phase I Evaluation (2005) (125)
- Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. (2014) (125)
- Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study. (2019) (123)
- Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). (2020) (122)
- Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. (2004) (120)
- Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response (2013) (117)
- A phase 2 trial of dasatinib in advanced melanoma (2011) (109)
- Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). (2013) (109)
- A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. (2019) (108)
- A Melanoma Brain Metastasis with a Donor-Patient Hybrid Genome following Bone Marrow Transplantation: First Evidence for Fusion in Human Cancer (2013) (104)
- A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. (1991) (103)
- Exome sequencing identifies recurrent somatic RAC 1 mutations in melanoma (2016) (103)
- Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. (2016) (103)
- PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors (2017) (101)
- Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. (2003) (101)
- Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. (2015) (100)
- High-dose aldesleukin in renal cell carcinoma: long-term survival update. (1997) (99)
- Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. (2018) (98)
- Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy (2020) (97)
- The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization (2007) (94)
- MicroRNA signatures differentiate melanoma subtypes (2011) (94)
- Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. (2010) (94)
- Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. (2003) (94)
- A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders. (2008) (94)
- Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis. (2014) (89)
- Plasma Markers for Identifying Patients with Metastatic Melanoma (2011) (89)
- White Paper on Adoptive Cell Therapy for Cancer with Tumor-Infiltrating Lymphocytes: A Report of the CTEP Subcommittee on Adoptive Cell Therapy (2011) (88)
- Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer (2005) (87)
- Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial (2016) (86)
- Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. (1990) (85)
- A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer (2004) (84)
- Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce (2020) (83)
- Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. (1990) (82)
- Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. (2019) (81)
- Biology of advanced uveal melanoma and next steps for clinical therapeutics (2014) (79)
- LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY (2014) (76)
- Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer (2019) (75)
- Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. (2014) (72)
- A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). (2017) (71)
- Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial. (2013) (70)
- Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. (2014) (69)
- Role of chitinase 3-like-1 and semaphorin 7a in pulmonary melanoma metastasis. (2015) (69)
- Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma (2020) (68)
- Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up. (2013) (67)
- Ipilimumab-induced perforating colitis. (2013) (67)
- Integrative Analysis of Epigenetic Modulation in Melanoma Cell Response to Decitabine: Clinical Implications (2009) (67)
- Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. (2007) (65)
- IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). (2017) (63)
- Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. (2014) (63)
- Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. (1994) (62)
- Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 (2020) (60)
- T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma (2022) (60)
- Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer. (1998) (59)
- KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements (2021) (59)
- Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells (2008) (53)
- A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia (2004) (53)
- Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC). (2015) (52)
- Toxicity and Activity of a Twice Daily High-dose Bolus Interleukin 2 Regimen in Patients With Metastatic Melanoma and Metastatic Renal Cell Cancer (2008) (52)
- A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma (2017) (51)
- Human gene marker/therapy clinical protocols. (1999) (51)
- Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies. (2016) (50)
- Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. (2006) (49)
- NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT. (2018) (48)
- Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2a. (1991) (48)
- Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma. (1989) (47)
- Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma (2019) (47)
- Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab. (2013) (45)
- Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. (2019) (45)
- Melanoma: A model for testing new agents in combination therapies (2010) (44)
- Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine. (1990) (42)
- A Variant in a MicroRNA Complementary Site in the 3′UTR of the KIT Oncogene Increases Risk of Acral Melanoma (2010) (41)
- Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition. (2019) (40)
- Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma (2019) (39)
- Key issues in the management of gastrointestinal immune-related adverse events associated with ipilimumab administration (2013) (39)
- Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects. (1993) (39)
- Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia (2005) (38)
- Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases. (2010) (38)
- Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases. (2015) (38)
- Melanoma brain metastases: is it time to reassess the bias? (2011) (37)
- Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma. (1992) (37)
- Cyclosporine for Dry Eye Associated With Nivolumab: A Case Progressing to Corneal Perforation (2016) (36)
- Dose-related immunologic effects of levamisole in patients with cancer. (1993) (36)
- Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies (2016) (36)
- Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma (2020) (36)
- Expression of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptors 1 and 2 in Melanoma (2006) (35)
- Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series. (2019) (35)
- Blockade of the B7-H1/PD-1 Pathway as a Basis for Combination Anticancer Therapy (2014) (35)
- C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas (2009) (35)
- A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies. (2011) (34)
- A Phase I Trial of B7-Transfected or Parental Lethally Irradiated Allogeneic Melanoma Cell Lines to Induce Cell-Mediated Immunity Against Tumor-Associated Antigen Presented by HLA-A2 or HLA-A1 in Patients with Stage IV Melanoma. National Institutes of Health, Bethesda, Maryland (1995) (34)
- Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma. (2011) (33)
- Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL). (2013) (33)
- Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity. (1997) (33)
- Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma (2016) (33)
- Erythropoietin production. A potential marker for interleukin‐2/interferon‐responsive tumors (1993) (32)
- Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study (2020) (32)
- A Phase II Clinical Trial of Interleukin‐2 and Lymphokine‐Activated Killer Cells in Advanced Colorectal Carcinoma (1994) (32)
- Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma. (2010) (31)
- Genitourinary tumors, non-prostate (2012) (31)
- Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma (2021) (30)
- 809OIMMUNE CORRELATES AND LONG TERM FOLLOW UP OF A PHASE IA STUDY OF MPDL3280A, AN ENGINEERED PD-L1 ANTIBODY, IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC). (2014) (30)
- A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2b. (1990) (29)
- BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM). (2013) (29)
- Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer. (1996) (29)
- Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes. (2015) (29)
- Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma. (1989) (26)
- Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma (2017) (26)
- Use of prophylactic antibiotics for prevention of intravascular catheter-related infections in interleukin-2-treated patients. (1989) (25)
- Phase II Trial of Interleukin 1α and Indomethacin in Treatment of Metastatic Melanoma (1996) (25)
- A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1 (2021) (25)
- Chitinase-like proteins in lung injury, repair, and metastasis. (2012) (23)
- Betting on immunotherapy for melanoma (2009) (23)
- Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) (2014) (23)
- Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab (2014) (23)
- Molecular Markers of Response to Treatment for Melanoma (2011) (22)
- Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study. (1992) (22)
- High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma. (1995) (22)
- Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma. (1991) (22)
- Antigen-specific agents in development. (1997) (22)
- Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12. (2005) (21)
- Therapeutic combinations of immune-modulating antibodies in melanoma and beyond. (2015) (21)
- Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL). (2012) (21)
- Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients. (1996) (21)
- A phase II trial of dasatinib in advanced melanoma. (2009) (20)
- 1085OSURVIVAL, RESPONSE DURATION, AND ACTIVITY BY BRAF MUTATION (MT) STATUS IN A PHASE 1 TRIAL OF NIVOLUMAB (ANTI-PD-1, BMS-936558, ONO-4538) AND IPILIMUMAB (IPI) CONCURRENT THERAPY IN ADVANCED MELANOMA (MEL). (2014) (20)
- Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic stage IV melanoma (2019) (20)
- Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) (20)
- Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy. (2017) (19)
- Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis (2018) (19)
- Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab. (2019) (19)
- Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors. (2017) (19)
- A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma. (1995) (19)
- Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype? (2010) (19)
- A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma. (2001) (18)
- Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin. (1999) (18)
- Cancer Immunotherapy: Past Progress and Future Directions. (2015) (18)
- A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer (2005) (18)
- A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma. (1996) (18)
- Interleukin-2 in therapy of hematologic malignancies [editorial; comment] (1994) (18)
- Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors. (2015) (18)
- Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7 th2010" (2011) (18)
- Immune Modulation Therapy and Imaging: Workshop Report (2017) (17)
- A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate (ADC) targeting glycoprotein NMB (GPNMB) in patients (pts) with advanced melanoma. (2016) (17)
- Phase Ib study of PF-05082566 in combination with pembrolizumab in patients with advanced solid tumors. (2016) (17)
- Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC). (2012) (16)
- Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. (2020) (16)
- Clinical applications of IL-2. (1994) (16)
- Hepatic toxicity of drugs used for hematologic neoplasia. (1987) (15)
- Diminished but not dead: chemotherapy for the treatment of NSCLC. (2016) (15)
- Release the hounds! Activating the T-cell response to cancer. (2015) (15)
- Interleukin-2 in therapy of hematologic malignancies. (1994) (15)
- Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC (2021) (15)
- A phase II trial of extracorporeal plasma immunoadsorption of patient plasma with prosorba columns for treating metastatic breast cancer (1995) (14)
- A phase I/II study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III/IV melanoma (2008) (13)
- Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results. (2012) (13)
- A novel anti-melanoma SRC-family kinase inhibitor (2019) (13)
- First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study. (2017) (13)
- Melanoma and other skin tumors (2012) (13)
- Advances in the treatment of metastatic melanoma: new immunomodulatory agents. (2012) (13)
- In vitro studies of dasatinib, its targets and predictors of sensitivity (2011) (13)
- Melanoma and immunotherapy bridge 2015 (2016) (13)
- Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. (2012) (13)
- A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence (2015) (12)
- VEGF, VEGFR1, and VEGFR2 expression in melanoma (2007) (12)
- A phase 1 multicenter open-label dose-escalation study of BMS-936561 (MDX-1203) in clear cell renal cell carcinoma (ccRCC) and B-cell non Hodgkin lymphoma (B-NHL). (2014) (11)
- Chemotherapy drug interactions with biological agents. (1993) (11)
- Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218) (2020) (11)
- Resistance mechanisms to checkpoint inhibitors. (2021) (11)
- Adrenal insufficiency and interleukin-2 therapy. (1989) (11)
- Clinical activity and safety of antiprogrammed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with previously treated, metastatic renal cell carcinoma (mRCC): An updated analysis. (2013) (10)
- A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors. (2017) (10)
- Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant (2015) (10)
- Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma. (1996) (9)
- Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer (2017) (9)
- Pre-treatment patient selection for nivolumab benefit based on serum mass spectra (2015) (9)
- Pharmacokinetics (PK) of CR011-vcMMAE, an antibody-drug conjugate (ADC), in a phase (Ph) I study of patients (pts) with advanced melanoma. (2016) (8)
- 5-Fluorouracil plus levamisole: effective adjuvant treatment for colon cancer. (1990) (8)
- Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors (2022) (8)
- Evaluation of clinical endpoints as surrogates for overall survival in patients treated with immunotherapies. (2017) (8)
- Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T). (2013) (8)
- Phase I Trial of Triapine–Cisplatin–Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers (2017) (8)
- Abstract CT106: A phase I/IIa study of IMCgp100: Partial and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma (2015) (8)
- A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol 9401. (1995) (8)
- A phase I clinical trial of flavone-8-acetic acid in combination with interleukin 2. (1995) (8)
- Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. (2021) (8)
- Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM). (2017) (8)
- Revisiting Anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy. (2020) (8)
- Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis (2022) (8)
- Advances in the systemic treatment of metastatic melanoma. (2013) (8)
- Biologic therapies for low-grade lymphomas. (1993) (8)
- Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases (2021) (8)
- 1051PDIMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN PREVIOUSLY TREATED AND UNTREATED METASTATIC RENAL CELL CARCINOMA (MRCC): BIOMARKER-BASED RESULTS FROM A RANDOMIZED CLINICAL TRIAL. (2014) (7)
- Identification of adenosine pathway genes associated with response to therapy with the adenosine receptor antagonist CPI-444. (2018) (7)
- Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function (2022) (7)
- Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL). (2017) (7)
- Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study (2022) (7)
- Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review (2022) (6)
- Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers (2012) (6)
- Anti-PD-1 (BMS-936558/MDX-1106/ONO-4538) in Patients With Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers (2012) (6)
- First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors (2022) (6)
- Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2a in patients with metastatic melanoma. A phase II Study. (1992) (6)
- Prolonged , Continuous Treatment of Hairy Cell Leukemia Patients With Recombinant Interferon-da (2003) (6)
- Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (2013) (6)
- Clinical trials referral resource. NCI-sponsored trials of interleukin-6 (IL-6). (1993) (6)
- Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. (2012) (5)
- 1088PDLONG-TERM SURVIVAL OF IPILIMUMAB-NAïVE PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL) TREATED WITH NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN A PHASE 1 TRIAL. (2014) (5)
- 785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL) (2022) (5)
- 420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study (2020) (5)
- 1212TiPPIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies (2017) (4)
- A phase I and pharmacokinetic study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III /IV melanoma (2007) (4)
- Relationship between clinical efficacy and AEs of IMCgp100, a novel bispecific TCR–anti-CD3, in patients with advanced melanoma. (2019) (4)
- A Phase II trial of pembrolizumab for patients with melanoma or non-small cell lung cancer and untreated brain metastases (2017) (4)
- Clinical Trials Referral Resource. Trials using tumor vaccines. (1997) (4)
- Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma: Analysis from KEYNOTE-006. (2021) (4)
- P2.07-062 PIVOT-02: Phase 1/2 Study of NKTR-214 and Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies (2017) (4)
- Combination immunotherapy: Where do we go from here? (2015) (4)
- Clinical Activity and Safety of Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Previously Treated, Metastatic Renal Cell Carcinoma (MRCC) (2012) (4)
- TUMOR ANTIGENS AS TARGETS FOR ANTICANCER DRUG DEVELOPMENT (2002) (4)
- Analysis of pre-treatment O-6-alkylguanine transferase (AGT) levels in patients (pts) with hematologic malignancies receiving VNP40101M (101M). (2005) (4)
- Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanoma (2022) (3)
- Effect of NKTR-214 on the number and activity of CD8+ tumor infiltrating lymphocytes in patients with advanced renal cell carcinoma. (2017) (3)
- Phase Ib, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumours (2019) (3)
- Pharmacodynamic effect of IMCgp100 (TCR–CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma. (2019) (3)
- CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL). (2019) (3)
- Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL) (2016) (3)
- Adoptive cellular therapy. (1992) (3)
- Antibodies and Recombinant Cytokines (2005) (3)
- Tumour therapy using Salmonella (2000) (3)
- Expanded use trials-are there better approaches to minimize adverse consequences to the clinical trials program? (2014) (2)
- Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma. (2019) (2)
- Introducing a New Series: Immunotherapy Facts and Hopes (2018) (2)
- A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies. (2020) (2)
- Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstracts (2020) (2)
- Challenges in Conducting Clinical Research on Patients With Advanced Melanoma. (2017) (2)
- Abstract CT329: A Phase I study of IMCgp100: durable responses with a novel first-in-class immunotherapy for advanced melanoma (2014) (2)
- Immune monitoring of cancer vaccines. Report on a workshop held at the 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy. (1996) (2)
- Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL). (2016) (2)
- A phase I study of sunitinib in combination with sirolimus in adults with advanced refractory malignancies. (2009) (2)
- Cytokine release syndrome (CRS) following treatment with tebentafusp, a novel bispecific TCR-anti-CD3 directed against gp100, in patients with advanced melanoma (2019) (2)
- A Phase I trial of the sulfonylhydrazine alkylator, VNP40101M (101M), administered weekly in patients (pts) with metastatic cancer. (2004) (1)
- Clinical significance of programmed death ligand-1 expression in non-small cell lung cancer (NSCLC). (2013) (1)
- Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab (2015) (1)
- Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006 (2017) (1)
- Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors (2021) (1)
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) (1)
- Combination Strategies PD-1/PD-L1 Antagonists. (2018) (1)
- T-cell adoptive immunotherapy: moving ahead by going in a circle. (2000) (1)
- Revisiting ribonucleotide reductase as a target to enhance radiation and chemotherapy anti-tumor activity. (2003) (1)
- Dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1). (2022) (1)
- Dhodapkar NY-ESO-1 to the Dendritic Cell Receptor DEC-205 Induction of Antigen-Specific Immunity with a Vaccine Targeting (2014) (1)
- Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications (2023) (1)
- Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02. (2022) (1)
- Integrative molecular and clinical profiling of acral melanoma identifies LZTR1 as a key tumor promoter and therapeutic target (2021) (1)
- Abstract 1477: Tumor cell-leukocyte fusion in human cancer: A melanoma brain metastasis with a donor-patient hybrid genome following allogeneic BMT (2011) (1)
- Clinical trials referral resource. Tumor Vaccine Trials. (1998) (1)
- Phase II Trial of High-Dose Interleukin-2 and Lymphokine-Activated Killer Cells in Hodgkin's Disease and Non-Hodgkin's Lymphom (1991) (1)
- Distinct dominant T-cell receptors with a tissue resident memory phenotype in individual melanoma metastases. (2017) (1)
- Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC) (2022) (1)
- RBTT-07. A PHASE 2 TRIAL OF PEMBROLIZUMAB AND BEVACIZUMAB IN MELANOMA BRAIN MET PATIENTS (2019) (1)
- Pathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy (2019) (1)
- 389 Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy (2021) (1)
- Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab (2014) (1)
- Phase II trial of Voyager-V1 (vesicular stomatitis virus expressing human IFNβ and NIS, VV1), in combination with cemiplimab (C) in patients with NSCLC, melanoma, HCC or endometrial carcinoma. (2020) (1)
- TUMOR VACCINE TRIALS (1998) (1)
- Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma. (2023) (1)
- 772 A phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01) (2022) (1)
- Changes in serum IL8 levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients (2016) (1)
- Abstract CT041: Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1) (2022) (1)
- Abstract PR05: Combination therapy with anti-CTLA4 and anti-PD1 leads to distinct immunologic changes in-vivo (2015) (0)
- Adoptive cellular therapy. (1991) (0)
- Phase I Study of Triapine® and Cytarabine (ara-C) in Patients with Relapsed or Refractory Acute Leukemias and High-Risk Myelodysplastic Syndrome (MDS). (2005) (0)
- 3:30 PM Abstract No. 345 Safety and feasibility of immuno-cryotherapy (2018) (0)
- Parkinson comment ] Interleukin-2 in therapy of hematologic malignancies (2002) (0)
- TIL in Melanoma—Similar Approaches, Different Results, Unanswered Questions (2021) (0)
- Coupled fibromodulin and SOX2 signaling as a critical regulator of distant metastasis initiation in melanoma (2022) (0)
- Developing enabling technologies for the success of cancer immunotherapy. (2004) (0)
- A 71-year-old woman with decreased vision, nyctalopia, and peripheral vision loss. (2016) (0)
- An exploratory study to investigate the immunomodulatory activity of BMS-936558 in patients with metastatic clear-cell renal cell carcinoma. (2012) (0)
- Phase I and Pharmacokinetic Study of Triapine , a Potent Ribonucleotide Reductase Inhibitor , Administered Daily for Five Days in Patients with Advanced Solid Tumors 1 (2003) (0)
- Selective accumulation of attenuated Salmonella in solid tumors - a new anti-cancer vector (2001) (0)
- ISY9-3Proteomic and T cell biomarkers identify sensitivity and resistance to immunotherapy in cancer patients (2017) (0)
- KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements (2021) (0)
- Safety and feasibility of immuno-cryotherapy. (2018) (0)
- Abstract 6670: Association between circulating CD4 memory T cell levels and severe immune-related adverse events in melanoma patients treated with immune checkpoint blockade (2023) (0)
- Melanoma and immunotherapy bridge 2015 (2016) (0)
- a Peptide Vaccine Patients with Metastatic Melanoma Receiving Generation of Antitumor Reactivity in Impact of Cytokine Administration on the (1999) (0)
- Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy (2020) (0)
- Outcomes of Melanoma Brain Metastasis Management with Gamma Knife Radiosurgery +/- Ipilimumab (2011) (0)
- Relative roles of targeted therapies and immunotherapies in melanoma. (2012) (0)
- Adoptive Immunotherapy (2003) (0)
- Adoptive immunotherapy. (2020) (0)
- Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives—a meeting report (2020) (0)
- Safety and Efficacy of Pembrolizumab in US Patients Enrolled in KEYNOTE-030, an Expanded Access Program (2015) (0)
- Tissue resident memory T cells create genetically distinct immune microenvironments within melanoma metastasis (2015) (0)
- Validation of the prognostic utility of the gene expression profiling test in patients with uveal melanoma. (2023) (0)
- Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer (2014) (0)
- 1085O SURVIVAL, RESPONSE DURATION, AND ACTIVITY BY BRAF MUTATION (MT) STATUS IN A PHASE 1 TRIALOF NIVOLUMAB (ANTI-PD-1, BMS-936558, ONO-4538) AND IPILIMUMAB (IPI) CONCURRENT THERAPY IN ADVANCEDMELANOMA (MEL) (2014) (0)
- Author Correction: Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis (2022) (0)
- Clinical predictors of longer survival in patients with BRAFV600-mutated metastatic melanoma receiving immunotherapy prior to BRAF/MEK inhibition in the metastatic setting. (2022) (0)
- Phase I S tudy o f t he I ntravenous A dministration o f Attenuated Salmonella t yphimurium to P atients W ith Metastatic M elanoma (2002) (0)
- A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2R af Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors (2019) (0)
- Immunotherapy for cancer: focusing on developing treatments rather than drugs. (2001) (0)
- Ablation of Histone Demethylase KDM5B in Melanoma Augments Anti-Tumor Immunity through Upregulation of Retroelements (2020) (0)
- 9306 Phase II multi-institution trial of ipilimumab for patients with melanoma and brain metastasis (2009) (0)
- 21 Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients (2020) (0)
- Human gene marker/therapy clinical protocols. (2000) (0)
- Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors (2019) (0)
- Anti-CD 3 Monoclonal Antibody Treatment of Patients with CD 3-Negative Tumors : A Phase IA / B Study 1 (2006) (0)
- Abstract 3287: A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better (2023) (0)
- Abstract 1179: Rational combinations with the dual RAF/MEK inhibitor VS-6766 for treatment of cutaneous melanoma harboring BRAF, NRAS, NF1 or CRAF mutations (2022) (0)
- IS5-4CHECKPOINT INHIBITORS AS A FOUNDATION FOR ANTI-CANCER IMMUNE THERAPY (2014) (0)
- Immunotherapy earns its spot in the ranks of cancer therapy (2012) (0)
- Relationship between clinical efficacy and AEs of tebentafusp, a novel bispecific TCR-anti-CD3, in patients with advanced melanoma (2020) (0)
- Mario Sznol, MD on the Future of Addressing Drug Resistance (2019) (0)
- Abstract 1306: Biomarker results from a clinical trial of nivolumab in patients (pts) with metastatic renal cell carcinoma (mRCC) (CA209-009): Gene expression, serum profiling for immune markers, and multiplex tissue immunohistochemistry (IHC) (2015) (0)
- What is the first-line treatment of choice for metastatic BRAF-mutant melanoma? (2012) (0)
- Clinical trials referral resource. Tumor vaccine clinical trials. (1995) (0)
- Expression and prognostic value of TRAIL receptors R1 and R2 in early stage breast cancer (2005) (0)
- The Phoenix Rises: The Rebirth of Cancer Immunotherapy. (2017) (0)
- What Tx is your first choice for metastatic BRAF+ melanoma? (2011) (0)
- Melanoma patients with durable responses to IL-2 treatment: role of surgical salvage for persistent or recurrent disease (1997) (0)
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab (2023) (0)
- Evaluating the Medical Management of Locally Advanced and Metastatic Basal Cell Carcinoma: A Single Institutional Retrospective Analysis Investigating Efficacy, Safety, and Tolerability (2023) (0)
- Pharmacodynamic effect of tebentafusp (TCR-CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma (2020) (0)
- Phase I study of VNP40101M (101M) and AraC in patients (pts) with refractory leukemia (2004) (0)
- Abstracts from the 4th ImmunoTherapy of Cancer Conference (2017) (0)
- A proteomic biomarker discovery platform for predicting clinical benefit of immunotherapy in advanced melanoma. (2020) (0)
- Abstract CT034: GLIMMER-01: initial results from a phase 1 dose escalation trial of a first-in-class bi-sialidase (E-602) in solid tumors (2023) (0)
- Reversing Resistance to Checkpoint Inhibitors and Targeted Therapy in Metastatic Melanoma. (2020) (0)
- Phase I study of VNP40101M (101M) and AraC in patients (pts) with refractory leukemia. (2004) (0)
- High-Dose R ecombinant I nterleukin 2 T herapy f or P atients With M etastatic M elanoma: A nalysis o f 2 70 P atients Treated B etween 1 985 a nd 1 993 (1999) (0)
- Treatment of Melanoma with Agonist Immune Costimulatory Agents (2012) (0)
- CommentaryA model for testing new agents in combination therapies (2010) (0)
- Immunotherapy Bridge 2020 and Melanoma Bridge 2020: meeting abstracts (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Mario Sznol?
Mario Sznol is affiliated with the following schools: